Following a period of twenty-one days, the analysis of tumor growth curve, tumor sizes, tumor weight and Ki67 staining demonstrated that EGR1 downregulation significantly stimulated tumor growth in the in vivo setting (Fig. 2F, G). The gene discussed is EGR1; the disease is neoplasm.